The improvement in discrimination gained by adding nontraditional cardiovascular risk markers cited in
METHODS
The MESA study design has been published previously (3) . Briefly, MESA is a prospective population- For the present analysis, participants were excluded who had missing data related to traditional or additional risk factors or to follow-up; also excluded were those who were using statins at baseline. Our analyses were restricted to participants age 40 to 75 years because they were identified in the guidelines as having the strongest data indicating a benefit from statin therapy for primary prevention. 
ADDITIONAL GUIDELINE-RECOMMENDED RISK MARKERS.
Determining the presence of genetic hyperlipidemias, as recommended in the guidelines (2), was not assessed in the present analysis because this information was not collected in MESA. Also, we did not assess lifetime ASCVD risk because it can only be calculated in adults age 20 to 59 years, and many MESA participants are age >59 years. In addition, to create the lifetime risk calculator, only cohorts with >15 years of follow-up were included, which is beyond the duration of follow-up in MESA.
FH OF ASCVD. In MESA, we did not specifically define FH of ASCVD as premature (i.e., before the age of 55 years for men and 65 years for women). Instead, These potential confounders were chosen based on their association with incident ASCVD in previous studies and also in our univariate analysis.
. Do the additional risk markers improve discrimination
over and beyond the calibrated PCEs? The PCE was known to overestimate risk in MESA (9) . Thus, to avoid overstating the contribution of the additional risk factors in improving the PCE risk estimates, the PCE was recalibrated to the MESA data. Calibration was accomplished by including the PCE in a Cox model predicting ASCVD events (10); this approach created a calibrated pooled cohort equation (cPCE), which used the baseline survival estimate from the MESA data and thus reduced the risk overestimation presented in the original PCE/score. These cPCEs were used in all subsequent analyses. Ten-year cPCE was calculated for each participant, including subjects with type 2 DM. The cPCE included race-specific risk estimates for black and white subjects only; risk estimates for Hispanic and Chinese participants were calculated by using the cPCE for white subjects, as suggested in the new guidelines.
Discrimination was assessed by using Harrell's C statistic for the cPCE with and without each additional risk marker (11, 12) . Cross-tabulation of the cPCE with and without each additional risk marker
Nontraditional ASCVD Risk Markers was performed to calculate the net reclassification improvement (NRI). Bootstrapping was used to calculate 95% confidence intervals (CIs) (13) . The NRI analyses for events and nonevents were calculated separately, as previously recommended. The NRI analyses were conducted by using the 7.5% ASCVD risk cutoff, per the ACC/AHA guidelines (2 categories).
Three categories of ASCVD risk (0% to 5%, 5% to 7.5%, and >7.5%) were also used as a sensitivity analysis.
The improvement in Harrell's C statistics and NRI of the additional risk markers were directly compared. In a subsequent analysis, the Framingham risk score (14) was recalibrated as described for the PCE, and the improvement in reclassification afforded by the addition of these additional risk markers (CAC score, ABI, hsCRP levels, and FH) was assessed by using Harrell In terms of the added value of the additional risk markers, CAC score, ABI, and FH were each independent predictors of incident ASCVD events in multivariable Cox models ( Table 2 ). Online Table 1 shows the hazard ratios and 95% CIs of the additional risk markers and the covariates in the multi- -0.004 to 0.011). Using 3 ASCVD risk categories (0% to 5%, 5% to 7.5%, and >7.5%) instead of the 2 categories Table 2 ) for all the additional risk markers considered. Total NRI for ABI 0.017 (-0.031 to 0.058)
Values are n or n (%) unless otherwise indicated.
FH ¼ family history; NRI ¼ net reclassification improvement; other abbreviations as in Tables 1 and 2 . Values are n or n (%) unless otherwise indicated. Calibrated Framingham risk score (cFRS) for coronary heart disease events, which include myocardial infarction and coronary heart disease-related death.
Abbreviations as in Tables 1 to 3 .
DISCUSSION
The goal of the present study was to assess the improvement in discrimination that would be gained by adding the recommended nontraditional risk markers to the 2013 cPCE. The present study found that among the 4 ACC/AHA-recommended nontraditional risk markers studied, the CAC score provides the highest (albeit, modest) improvement in discrimination over and beyond the cPCE (Central Illustration). The superiority of the CAC score seems to be consistent across all possible ASCVD strata. To our knowledge, this study is the first to assess whether nontraditional risk markers improve risk prediction afforded by the cPCE.
Previous studies showed that CAC score, ABI, hsCRP levels, and FH improve discrimination and classification of risk over the Framingham risk score but to varying degrees (15) (16) (17) (18) . Our group (19) , as well as a report by the Rotterdam study (15) , showed that among these 4 risk markers, CAC score provided the greatest improvement in discrimination across the whole CHD risk spectrum and also in those 
